SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

Authors

Allen Lee Cohn

Rocky Mountain Cancer Centers, Denver, CO

Allen Lee Cohn , J. Randolph Hecht , Shaker Dakhil , Mansoor N. Saleh , Bilal Piperdi , Vivian Jean M. Cline-Burkhardt , Ying Tian , William Y. Go

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT00418938

Citation

J Clin Oncol 31, 2013 (suppl; abstr 3616)

DOI

10.1200/jco.2013.31.15_suppl.3616

Abstract #

3616

Poster Bd #

11B

Abstract Disclosures

FEATURED

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).